Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target
BackgroundAspartate β-hydroxylase (ASPH) is an embryonic transmembrane protein aberrantly upregulated in cancer cells, associated with malignant transformation and, in some reports, with poor clinical prognosis.ObjectiveTo report the expression patterns of ASPH in acute myeloid leukemia (AML).Method...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.783744/full |
| _version_ | 1818974814974509056 |
|---|---|
| author | Noa G. Holtzman Noa G. Holtzman Michael S. Lebowitz Rima Koka Maria R. Baer Maria R. Baer Kanam Malhotra Amir Shahlaee Hossein A. Ghanbari Søren M. Bentzen Søren M. Bentzen Ashkan Emadi Ashkan Emadi Ashkan Emadi |
| author_facet | Noa G. Holtzman Noa G. Holtzman Michael S. Lebowitz Rima Koka Maria R. Baer Maria R. Baer Kanam Malhotra Amir Shahlaee Hossein A. Ghanbari Søren M. Bentzen Søren M. Bentzen Ashkan Emadi Ashkan Emadi Ashkan Emadi |
| author_sort | Noa G. Holtzman |
| collection | DOAJ |
| description | BackgroundAspartate β-hydroxylase (ASPH) is an embryonic transmembrane protein aberrantly upregulated in cancer cells, associated with malignant transformation and, in some reports, with poor clinical prognosis.ObjectiveTo report the expression patterns of ASPH in acute myeloid leukemia (AML).MethodsCell surface expression of ASPH was measured via 8-color multiparameter flow cytometry in 41 AML patient samples (31 bone marrow, 10 blood) using fluorescein isothiocyanate (FITC)-conjugated anti-ASPH antibody, SNS-622. A mean fluorescent intensity (MFI) of 10 was used as a cutoff for ASPH surface expression positivity. Data regarding patient and disease characteristics were collected.ResultsASPH surface expression was found on AML blasts in 16 samples (39%). Higher ASPH expression was seen in myeloblasts of African American patients (p=0.02), but no correlation was found between ASPH expression and other patient or disease characteristics. No association was found between ASPH status and CR rate (p=0.53), EFS (p=0.87), or OS (p=0.17).ConclusionsASPH is expressed on blasts in approximately 40% of AML cases, and may serve as a new therapeutically targetable leukemia-associated antigen. |
| first_indexed | 2024-12-20T15:46:03Z |
| format | Article |
| id | doaj.art-f86fb60e39bc4aa5ab5969a96ee00ea4 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-20T15:46:03Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f86fb60e39bc4aa5ab5969a96ee00ea42022-12-21T19:34:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-12-011110.3389/fonc.2021.783744783744Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic TargetNoa G. Holtzman0Noa G. Holtzman1Michael S. Lebowitz2Rima Koka3Maria R. Baer4Maria R. Baer5Kanam Malhotra6Amir Shahlaee7Hossein A. Ghanbari8Søren M. Bentzen9Søren M. Bentzen10Ashkan Emadi11Ashkan Emadi12Ashkan Emadi13Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United StatesImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesSensei Biotherapeutics Inc., Gaithersburg, MD, United StatesDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, United StatesMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United StatesDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD, United StatesSensei Biotherapeutics Inc., Gaithersburg, MD, United StatesSensei Biotherapeutics Inc., Gaithersburg, MD, United StatesSensei Biotherapeutics Inc., Gaithersburg, MD, United StatesMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United StatesDepartment of Epidemiology and Biostatistics, University of Maryland School of Medicine, Baltimore, MD, United StatesMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United StatesDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD, United StatesDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, United StatesBackgroundAspartate β-hydroxylase (ASPH) is an embryonic transmembrane protein aberrantly upregulated in cancer cells, associated with malignant transformation and, in some reports, with poor clinical prognosis.ObjectiveTo report the expression patterns of ASPH in acute myeloid leukemia (AML).MethodsCell surface expression of ASPH was measured via 8-color multiparameter flow cytometry in 41 AML patient samples (31 bone marrow, 10 blood) using fluorescein isothiocyanate (FITC)-conjugated anti-ASPH antibody, SNS-622. A mean fluorescent intensity (MFI) of 10 was used as a cutoff for ASPH surface expression positivity. Data regarding patient and disease characteristics were collected.ResultsASPH surface expression was found on AML blasts in 16 samples (39%). Higher ASPH expression was seen in myeloblasts of African American patients (p=0.02), but no correlation was found between ASPH expression and other patient or disease characteristics. No association was found between ASPH status and CR rate (p=0.53), EFS (p=0.87), or OS (p=0.17).ConclusionsASPH is expressed on blasts in approximately 40% of AML cases, and may serve as a new therapeutically targetable leukemia-associated antigen.https://www.frontiersin.org/articles/10.3389/fonc.2021.783744/fullleukemiamyeloidmyeloblastsASPHleukemia-associated antigen |
| spellingShingle | Noa G. Holtzman Noa G. Holtzman Michael S. Lebowitz Rima Koka Maria R. Baer Maria R. Baer Kanam Malhotra Amir Shahlaee Hossein A. Ghanbari Søren M. Bentzen Søren M. Bentzen Ashkan Emadi Ashkan Emadi Ashkan Emadi Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target Frontiers in Oncology leukemia myeloid myeloblasts ASPH leukemia-associated antigen |
| title | Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target |
| title_full | Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target |
| title_fullStr | Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target |
| title_full_unstemmed | Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target |
| title_short | Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target |
| title_sort | aspartate β hydroxylase asph expression in acute myeloid leukemia a potential novel therapeutic target |
| topic | leukemia myeloid myeloblasts ASPH leukemia-associated antigen |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.783744/full |
| work_keys_str_mv | AT noagholtzman aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT noagholtzman aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT michaelslebowitz aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT rimakoka aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT mariarbaer aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT mariarbaer aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT kanammalhotra aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT amirshahlaee aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT hosseinaghanbari aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT sørenmbentzen aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT sørenmbentzen aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT ashkanemadi aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT ashkanemadi aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget AT ashkanemadi aspartatebhydroxylaseasphexpressioninacutemyeloidleukemiaapotentialnoveltherapeutictarget |